Results 121 to 130 of about 60,559 (162)
Some of the next articles are maybe not open access.
Plasminogen Activator Inhibitor-1
2008Fibrinolysis, the dissolution of fibrin clots, is an integral component of the hemostatic system that involves the concerted action of a complex system of zymogens, activators, and inhibitors [1]. Plasmin, the primary protease of the fibrinolysic system, digests fibrin, thereby converting insoluble clot to soluble fibrin degradation products.
Daniel T. Eitzman +2 more
openaire +1 more source
Plasminogen activator inhibitor‐1 and diabetic nephropathy
Nephrology, 2005SUMMARY: Diabetic nephropathy is characterized by excessive accumulation of extracellular matrix (ECM) in the kidney. Decreased ECM degradation as well as increased ECM synthesis plays an important role in ECM remodeling that favours tissue fibrosis. Plasminogen activator (PA)/plasmin/PA inhibitor (PAI) system is involved in ECM degradation and PAI‐1 ...
Hi Bahl, Lee, Hunjoo, Ha
openaire +2 more sources
Development of Inhibitors of Plasminogen Activator Inhibitor-1
2011Plasminogen activator inhibitor-1 (PAI-1) belongs to the serine protease inhibitor super family (serpin) and is the primary inhibitor of both the tissue-type (tPA) and urokinase-type (uPA) plasminogen activators. PAI-1 has been implicated in a wide range of pathological processes where it may play a direct role in a variety of diseases.
Shih-Hon, Li, Daniel A, Lawrence
openaire +2 more sources
Plasminogen Activator Inhibitor-1 in Vascular Thrombosis
Current Drug Targets, 2007Thrombotic complications of vascular disease constitute the leading cause of morbidity and mortality in much of the developed world. Current drug therapies available to treat the thrombotic component of arterial and venous vascular complications remain limited.
Randal J, Westrick, Daniel T, Eitzman
openaire +2 more sources
A model of the active form of plasminogen-activator-inhibitor-1
Fibrinolysis, 1994A model of the reactive form of plasminogen activator inhibitor-1 (PAI-1) has been constructed using molecular graphics and starting from the known crystal structure of latent PAI-1. The residues P16 to P10', of which P16-P4 form strand 4 of the beta-sheet A (s4A) and P3-P10' form an extended loop in the latent form, have been removed and remodeled ...
K, Aertgeerts +3 more
openaire +2 more sources
Plasminogen activator inhibitor 1 in thrombotic disease
Current Opinion in Hematology, 1996Impaired fibrinolytic function, mainly due to an elevation of plasma plasminogen activator inhibitor 1 concentration, is a common finding in patients with thrombotic disease. In patients subjected to hip surgery, preoperatively increased levels of plasminogen activator inhibitor 1 seem to be predictive of postoperative deep venous thrombosis.
openaire +2 more sources
Genetic Architecture of Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1
Seminars in Thrombosis and Hemostasis, 2008Important biochemical constituents of the fibrinolytic system include tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). In the current review, we aim to describe the genetic architecture of t-PA and PAI-1. Several genetic polymorphisms in the T-PA and PAI-1 gene have been found to be associated with t-PA and PAI-1 ...
Asselbergs, Folkert W. +5 more
openaire +3 more sources
Urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor-1
Oncology Reports, 1997Tumor associated proteolysis is an essential mechanism in invasion and metastasis of cancer. The influence of the serine protease urokinase-like plasminogen activator (u-PA) and its inhibitor plasminogen activator inhibitor-1 (PAI-1) on the clinical prognosis of squamous carcinoma of the head and neck region (HNSCC) was evaluated. U-PA and PAI-1 levels
B, Wollenberg +4 more
openaire +2 more sources
Diabetes, 1995
Plasminogen activator inhibitor 1 (PAI-1) activity is increased in patients with non-insulin-dependent diabetes mellitus (NIDDM) and may contribute to their excess risk of cardiovascular disease. We examined the determinants of PAI-1 activity in 146 NIDDM subjects by using specific assays of insulin and intact and des-31,32-proinsulin and measures of ...
A, Panahloo +5 more
openaire +2 more sources
Plasminogen activator inhibitor 1 (PAI-1) activity is increased in patients with non-insulin-dependent diabetes mellitus (NIDDM) and may contribute to their excess risk of cardiovascular disease. We examined the determinants of PAI-1 activity in 146 NIDDM subjects by using specific assays of insulin and intact and des-31,32-proinsulin and measures of ...
A, Panahloo +5 more
openaire +2 more sources
Fibrinolysis, 1994
Abstract The relationship between PAI activity, active PAI-1 concentration and whole PAI-1 concentration was determined in 180 plasma samples of unselected ambulant patients of the department of internal medicine. To exclude a release of platelet PAI-1 after blood sampling, different anticoagulants and temperatures of blood storage were tested.
G. Siegert, Th. Fritz, E. Runge
openaire +1 more source
Abstract The relationship between PAI activity, active PAI-1 concentration and whole PAI-1 concentration was determined in 180 plasma samples of unselected ambulant patients of the department of internal medicine. To exclude a release of platelet PAI-1 after blood sampling, different anticoagulants and temperatures of blood storage were tested.
G. Siegert, Th. Fritz, E. Runge
openaire +1 more source